J Exp Clin Med 2014;6(6):IV–V
A
activin A 6:222
adverse drug event 6:139
analgesia 6:83
antibiotic resistance 6:16
antimicrobial stewardship 6:143
antinociception(analgesia) 6:151
anxiety disorders 6:179
articular cartilage defect 6:118
asthma 6:102
attention-deficit/hyperactivity
disorder 6:179, 190
atypical antipsychotic drug 6:111
autism spectrum disorder 6:179
autoimmune disease 6:57 B bacterial infection 6:94 benefit:cost ratio 6:139 biomechanics 6:203 bioreactor 6:10 bipolar disorder 6:111 bladder cancer 6:132 bone regeneration 6:10 breast 6:161 bupivacaine 6:83 C c-Jun 6:222 cancer 6:1 Candida infection 6:90 cephalexin 6:94 chemoprevention 6:132
children and adolescents 6:179
cholinergic effect 6:98
chronic inflammatory demyelinating
polyneuropathy 6:43
clinical predictor 6:43
colistin 6:213
communication difficulty 6:217
compulsive Internet use 6:190
critically ill patient 6:209
cytokines 6:50
cytomegalovirus colitis 6:209
D
demographic factors 6:102
dental implant 6:203
depot antipsychotic drug 6:200
diindolylmethane 6:132
DNA methylation 6:75
drug-resistant bacteria 6:143
dynorphin A1–17 6:151
E
electrical field stimulation 6:98
endoscopy 6:209 epidemiology 6:1 epidural anesthesia 6:83 epigenetics 6:75 erlotinib 6:98 erythroid genes 6:222 Escherichia coli 6:187 evidence-based practice 6:157 F fentanyl 6:83 finite-element method 6:203 G gefitinib therapy 6:50 genetic polymorphism 6:195 gold nanoparticles 6:172 Group B Streptococcus 6:187 H haloperidol 6:200
health service utilization 6:125
histone modifications 6:75
hospital-acquired pneumonia 6:157
human serum bactericidal activity 6:16
hyperalgesia 6:151 I immunotherapy 6:43 infant bacteremia 6:187 infant mortality 6:125 infants 6:1
Keyword Index
Keyword Index V infection control 6:157 interleukin-21 6:57 interleukin-21 receptor 6:57 K K562 cells 6:222 L length of hospitalization 6:90 leukemia 6:1 M medication adherence 6:200
medication management and use 6:139
mesenchymal stems cells 6:10
Met-enkephalin 6:151 metabolic syndrome 6:195 mitochondrial activity 6:21 mood disorders 6:179 mortality 6:90 N N-butyl-N-(4-hydroxybutyl) nitrosamine 6:132 nanomedicine 6:172 nasal packings 6:94 nerve excitability 6:43
non-small-cell lung cancer 6:50
noncoding RNAs 6:75 nosocomial infection 6:90, 143, 157, 213 O OSC2 cells 6:21 P peroxisome proliferator-activated receptor gamma 6:195
pervasive developmental disorder 6:179
pharmacist intervention 6:139, 143 phyllodes tumor 6:161 platelet-rich plasma 6:118 pneumonia 6:213 pulmonary function 6:102 Q quality of life 6:102, 125, 217 R recurrence 6:161
red blood cell hemagglutination 6:16
referral 6:217 reticuloendothelial system 6:172 rheumatoid arthritis 6:57 risperidone 6:111, 200 S schizophrenia 6:111 socioeconomic factors 6:125 solid tumors 6:1 Staphylococcus aureus 6:187 stress 6:203 swallowing difficulty 6:217 symptom cluster 6:50
synovial mesenchymal stem cells 6:118 T
thermosensitive hydrogel 6:118
three-dimensional dynamic culture 6:10
tigecycline 6:213
titanates 6:21
TNF-a 6:222
topical antibiotics 6:94
tracheal smooth muscle 6:98
W
